2011
DOI: 10.1007/s11934-011-0219-8
|View full text |Cite
|
Sign up to set email alerts
|

Bladder Dysfunction and Parkinsonism: Current Pathophysiological Understanding and Management Strategies

Abstract: Patients with Parkinson's disease (PD) commonly develop lower urinary tract symptoms (LUTS) as their disease severity progresses. It is a well-established fact that neurodegeneration of the nigrostriatal dopaminergic pathway occurs in PD. This neurochemical deficiency explains many of the motor disturbances encountered in patients with PD. However, the underlying cause of urinary dysfunction present in over half of patients with PD is poorly understood. Without clearly understanding the underlying pathophysiol… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 21 publications
(7 citation statements)
references
References 32 publications
(30 reference statements)
0
7
0
Order By: Relevance
“…Urinary tract infections are also common likely due to autonomic abnormalities leading to bowel and bladder dysfunction. Constipation or faecal impaction is another cause which may result in urinary retention and infections …”
Section: Discussionmentioning
confidence: 99%
“…Urinary tract infections are also common likely due to autonomic abnormalities leading to bowel and bladder dysfunction. Constipation or faecal impaction is another cause which may result in urinary retention and infections …”
Section: Discussionmentioning
confidence: 99%
“…1 Lower urinary tract symptoms (LUTS) occur in 7% to 70% of patients during the course of the disease that negatively influence health-related quality of life medication for at least 3 months prior to enrollment and if the dosage did not change over the duration of their participation in the study. 1 Lower urinary tract symptoms (LUTS) occur in 7% to 70% of patients during the course of the disease that negatively influence health-related quality of life medication for at least 3 months prior to enrollment and if the dosage did not change over the duration of their participation in the study.…”
Section: ■ Introductionmentioning
confidence: 99%
“…The pathophysiology underlying DU in PD is currently not well understood, although studies have correlated DU to the patient’s overall motor function 57 . Both pseudodyssynergia of the EUS during NDO and bradykinesia of the EUS during the onset of voluntary micturition can occur in PD patients 58 . Both of these EUS abnormalities can lead to impaired detrusor contractility and DU.…”
Section: Neurogenic Causes Of Detrusor Underactivitymentioning
confidence: 99%